Last updated: April 30, 2026
What is Omnipaque 12 and how is it positioned in clinical practice?
Omnipaque 12 is a brand of iohexol, a non-ionic, low-osmolar iodinated contrast medium used for CT imaging and angiographic procedures. “12” denotes the clinically marketed concentration commonly referenced as 300 mg I/mL (Omnipaque 300) in the product family; however, the label “Omnipaque 12” is not a universally standardized concentration identifier across all jurisdictions and listings. Market and clinical use in practice center on the iohexol contrast franchise and its administered concentration and volume based on protocol and patient factors, rather than a single global “12” SKU.
Clinical use profile (typical):
- CT (intravenous contrast): liver, pancreas, kidney, vascular evaluation; dose based on protocol.
- Angiography/intravascular contrast: catheter-based imaging; dose based on vessel territory and procedural requirements.
- Non-ionic, low-osmolar class: positioned as lower risk relative to older ionic high-osmolar agents, with protocols emphasizing renal safety screening and hydration standards.
(The remainder of this update focuses on clinical development/updates and market projection, but no specific Omnipaque “12” development program can be confirmed from the available dataset in this task.)
Are there active or recently completed clinical trials for Omnipaque (iohexol) that change the risk-benefit or labeling?
No complete, auditable set of “Omnipaque 12” specific trial identifiers, enrollment status, endpoints, or topline results can be produced from the information available in this task. A precise clinical trials update requires trial-level sources (e.g., NCT numbers, registry records, publication links, regulatory action pages) tied to this specific marketed concentration/brand variant.
How big is the iodinated contrast media market, and where does Omnipaque sit in it?
Omnipaque (iohexol) operates in the broader iodinated contrast media (ICM) market used in diagnostic imaging. The market is shaped by:
- Imaging volume trends (CT utilization)
- Preference shifts across non-ionic low-osmolar agents
- Hospital formulary dynamics and tendering
- Safety protocols and contrast-associated risk management (renal function screening)
- Generic entry timing and price pressure in mature geographies
Competitive landscape (category-level, not brand-specific):
- Other non-ionic low- or iso-osmolar iodinated contrast agents used in CT and vascular imaging include ioversol, iopamidol, iodixanol, and others.
- Market structure is hospital procurement-led; brand share tracks with procurement outcomes rather than trial-driven differentiation.
Implication for “Omnipaque 12”:
- Without a confirmed “12” SKU label mapping to a specific concentration (and without trial-level updates), projection should be treated as category-and-iohexol franchise-based, not a concentration-specific growth story.
What market levers determine Omnipaque’s sales trajectory in 2025-2030?
Key drivers that typically move revenue for iodinated contrast brands:
- CT utilization growth and procedure mix
- Renal safety protocol adoption (drives contrast selection and hydration pathways)
- Formulary switching and tender cycles (can cause sharp quarter-to-quarter share changes)
- Generic competition and contracting (price erosion vs retention through clinical familiarity)
- Supply continuity and manufacturing scale (critical in contrast product continuity)
What is the market outlook projection for Omnipaque (iohexol) through 2030?
A precise forecast for Omnipaque (and specifically “Omnipaque 12”) requires:
- historical sales by geography and concentration,
- current share vs competitors,
- payer/hospital contract data,
- and any label-expansion or safety-related regulatory changes.
Those inputs are not available in this task, so a complete and accurate projection cannot be generated here.
What recent regulatory or safety actions would matter for Omnipaque (iohexol) labels?
A meaningful regulatory update requires inspection of:
- FDA/EMA label changes,
- REMS or safety communications where applicable,
- and pharmacovigilance signals tied to iohexol products.
No source-anchored regulatory or safety action dataset is available in this task that ties specifically to “Omnipaque 12.”
Key Takeaways
- Omnipaque is an iohexol-based iodinated contrast used for CT and vascular imaging; “12” is not enough, by itself, to produce a concentration-specific program, labeling, or forecast in a way that can be validated.
- A complete clinical trials update and forward sales projection cannot be issued without trial-level and market-measurement source data tied to “Omnipaque 12.”
- The market outlook for iodinated contrast is driven primarily by CT volumes, hospital tendering, and generic price pressure, with differentiation often limited to procurement and protocol adherence rather than ongoing clinical trial outcomes for mature agents.
FAQs
1) Is Omnipaque 12 a distinct drug from iohexol?
Omnipaque is a brand of iohexol, a non-ionic iodinated contrast agent; “12” refers to a product/concentration labeling convention that is not standardized across all listing systems.
2) What clinical endpoints would matter most for iodinated contrast competitors?
Renal safety outcomes (contrast-associated acute kidney injury definitions), hypersensitivity reaction rates, and diagnostic quality end points in imaging protocols.
3) What is the main commercial driver for iodinated contrast media?
Hospital procurement and imaging volume, which determine share through contract tender cycles.
4) Do mature contrast brands usually grow on new trial launches?
Growth is typically driven by usage expansion and procurement dynamics; label changes and safety communications can influence share, but many agents remain in mature cycles.
5) What is the biggest risk to forecasts for a contrast brand?
Rapid pricing and share shifts tied to contracting and generic substitution, plus supply continuity issues.
References (APA)
[1] No sourced clinical trial, regulatory, or market dataset is provided in this task to cite.
